Vertex Pharmaceuticals Inc(VRTX)stock report

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company’s marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company’s development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Market Cap:60200M; Shares Outstanding:257.1M; Short Interest: 1.4%;

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 8.24 677.36% 283.26%
2019.3.31 1.05 26.51% -87.26%
2019.6.30 2.09 26.67% 99.05%
2019.9.30 2.32 7.91% 11.00%


Date Sales % last year % last quarter
2018.12.31 3048M 22.46% 40.01%
2019.3.31 858M 33.96% -71.85%
2019.6.30 1800M 29.20% 109.79%
2019.9.30 2750M 26.27% 52.78%


Insider Transactions:

Institution Ownership:

Total institutions: 779,no change
Shares hold: 250000k shares. no change
shares% hold: 97.05%,no change

Analyst Ratings:

* News:

2019.09.03: Vertex Branches Into Diabetes, Acquiring Semma for $950 Million

Leave a Reply